BioCentury
ARTICLE | Financial News

Merus inches up after IPO

May 20, 2016 12:21 AM UTC

Bispecific antibody developer Merus B.V. (NASDAQ:MRUS) rose $0.04 to $10.04 in its first day of trading Thursday after it raised $55 million through the sale of 5.5 million shares at $10 in an IPO. Earlier this month, it said it planned to sell 4.3 million shares at $14-$16. Citigroup, Jefferies, Guggenheim Securities and Wedbush PacGrow are underwriters. ...